Navigation Links
Caris Diagnostics Providing KRAS Mutational Analysis for Colon Cancer Patients
Date:6/24/2008

Providing Information on Response to Erbitux and Vectibix

IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix) developed by Amgen.

This assay, which can be performed on biopsies taken for the initial cancer diagnosis, identifies those patients who have somatic mutations in KRAS, which is associated with a lack of response to Erbitux or Vectibix. This prognostic information has recently been validated in a number of retrospective studies and will help better suggest which patients are most likely not going to respond to Erbitux or Vectibix, two chemotherapies widely being utilized to treat colon cancer. Caris Dx's KRAS assay is comprehensive in that it detects any and all nucleotide changes at the three validated KRAS codons (12, 13, and 61) that alter amino acids at these positions, offering a distinct advantage over other laboratories that may only screen for a few specific mutations in codons 12 and 13.

"Responding to oncologists needs for more and better information at the bedside, we are proud to be at the forefront of providing the newest, valuable molecular tests with the consistent quality and reproducibility that physicians have come to expect from Caris Dx," said Dr. Robert Penny, CEO of Caris MPI, the molecular profiling arm of Caris Dx. "We are excited to provide this vital information to clinicians at the time of their initial diagnosis to improve the likelihood of success with the patient's first therapy."

A recent Journal of Clinical Oncology study found that none of the 24 patients with confirmed KRAS mutations responded to Erbitux, whereas tumors shrank in 40% of those patients with the wild type (normal) KRAS gene. In another research study conducted in Belgium and published in March, Erbitux was ineffective in treating any of the 42 patients with a mutation, but proved effective in 27 of 66 patients with wild type KRAS. Amgen has also published a study noting that their drug Vectibix only works in patients with wild type KRAS. In Europe, Vectibix is only approved for patients who have wild type KRAS.

"The data are very compelling; research has clearly implicated KRAS as a vital biomarker for the assessment of response to Erbitux and Vectibix," said Dr. Daniel Von Hoff, Executive Director of Caris MPI's Pharmaceutical Services division, TGen Physician in Chief, and Chief Scientific Officer of US Oncology. "I think the oncology community is looking forward to having this type of information available in order to continue to develop more targeted, personalized treatment plans for patients."

KRAS mutation analysis is also being offered as part of Caris Dx's Target Now(TM) testing program. Target Now is an oncology testing service that utilizes cutting-edge molecular profiling techniques, including DNA microarray, advanced immunohistochemistries (IHC), fluorescent in-situ hybridization (FISH) and sequencing analysis, to provide molecular profiling information about a malignancy as an aid to a patient's oncologist. Each test report provides information on the molecular targets present in the cancer specimen for which there are believed to be associated therapies based on published literature. Furthermore, the report provides other additional information on the molecular profile of the patient's cancer.

At the beginning of 2008, Caris Diagnostics acquired Caris MPI in order to offer a single source solution to physicians seeking the highest quality medical opinions coupled with the most advanced molecular information available on a patient's tumor. The Company currently receives, processes and provides medical opinions on over one thousand GI biopsies per day. Caris MPI developed the KRAS mutation analysis so that it can be performed on these same biopsies without any need for additional coordination, or delay, and with the highest quality standards.

"Given our leading position in gastrointestinal pathology, it is not only natural, but also imperative for us to offer our clinicians this critical information for their treatment decisions," concluded David D. Halbert, Chairman of Caris Dx. "We have been predicting the convergence of anatomic pathology and molecular testing for some time. With our ability to perform the KRAS analysis on the biopsies that we receive for initial cancer diagnosis each week, the paths of anatomic and molecular test are now united. We look forward to adding further analyses to our Target GI testing panel in the future."

Physicians who are seeking additional information for their patients when considering treatment with Erbitux and/or Vectibix can order mutation analysis for KRAS by contacting 1-800-901-5177.

About Caris Diagnostics

Caris Diagnostics (Caris Dx) is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Caris Diagnostics provides world- class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of-the art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs. Through the molecular testing expertise of the Caris Molecular Profiling Institute (Caris MPI) at Caris Dx, the company also offers advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to provide critical information to physicians treating cancer and other complex diseases. In addition, Caris MPI supports pharmaceutical companies and other researchers in their clinical trials for targeted therapeutics with custom genomic and proteomic analyses, analyte preservation, tissue procurement and comprehensive reporting services. The company has strategic relationships with the International Genomics Consortium, US Oncology, the Translational Genomics Research Institute, and the Biodesign Institute of Arizona State University. More than 1,500 physicians nationally use Caris Diagnostics. Formed in 1996, the company is headquartered in Irving, Texas and operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); Newton, Massachusetts. Additional information is available at http://www.carisdx.com.


'/>"/>
SOURCE Caris Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
2. FDA Approves SOMA(R) (carisoprodol) 250 mg
3. Quest Diagnostics to Speak at the Jefferies 2nd Annual Healthcare Conference
4. Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Irelands First Nationwide Cervical-Cancer Screening Program
5. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
6. Johnson & Johnson Reviews Growth Strategies for Medical Devices & Diagnostics and Consumer Businesses
7. Johnson & Johnson to Host Medical Devices & Diagnostics and Consumer Business Review
8. Quest Diagnostics Chooses Roches Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
9. Quest Diagnostics Is Named Best Employer For Healthy Lifestyles
10. Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
11. Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran ... the JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight ... Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology: